| 摘要 |
PCT No. PCT/GB94/01802 Sec. 371 Date Aug. 22, 1996 Sec. 102(e) Date Aug. 22, 1996 PCT Filed Aug. 17, 1994 PCT Pub. No. WO95/05394 PCT Pub. Date Feb. 23, 1995Therapeutical and diagnostic agents for amyloidosis comprise molecules that inhibit the binding of serum amyloid P component to amyloid fibrils or analogues or homologues of the amyloid binding site on serum amyloid P component. The resolution of the complete three dimensional structure of serum amyloid P component enables inhibitors, binding site analogues and homologues to be designed by computer-aided molecular modelling. |
